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ABSTRACT
Because pretransplantation anti-thymocyte globulin (ATG) seems to reduce graft-versus-host-disease
(GVHD) and treatment-related mortality (TRM) after unrelated donor bone marrow transplantation (BMT),
we investigated this agent in matched related donor (MRD) blood cell transplantation (BCT). Fifty-four adults
receiving rabbit ATG, cyclosporine A, and methotrexate with myeloablative conditioning and undergoing first
MRD BCT were matched for disease and stage with 54 patients not given ATG. Most ATG-treated patients
had fludarabine with oral (7) or i.v. busulfan (46) with total body irradiation (TBI) in 10. Control patients
largely received TBI with VP16 (28) or oral busulfan with cyclophosphamide (15) or fludarabine (7). The ATG
was given at a total dose of 4.5 mg/kg over 3 d, finishing on day 0. Rates of acute GVHD (aGVHD) grade II-IV,
aGVHD grade III-IV, and chronic GVHD (cGVHD) were 19  5% versus 32  6% (P  .1), 6  3% versus
13  5% (P  NS), and 55  8% versus 96  3% (P  .002) in the ATG and control groups, respectively.
Patients given ATG had fewer sites involved by cGVHD compared with the control group (mean 2.1  0.2
versus 2.8  0.2, P  .04). Non-relapse mortality (NRM) with and without ATG, respectively, was 4  3%
versus 17  5% at 100 d and 9  4% versus 34  7% at 4 yr (P  .002). Deaths were GVHD related in 3
ATG-treated patients versus 14 controls (P  .007). Despite a trend to more relapse with ATG (43  7%
versus 22  7% at 4 yr, P  0.05), survival was 66  7% in the patients given ATG versus 50  7% in the
controls (P 0.046). This study indicates that myeloablative regimens incorporating fludarabine and oral or i.v.
busulfan with pretransplantation ATG given to recipients undergoing MRD BCT may result in less cGVHD,
lower TRM, and probably improved quality of life in survivors compared with previous protocols.
© 2007 American Society for Blood and Marrow Transplantation
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dNTRODUCTION
GVHD, acute (aGVHD) and chronic (cGVHD),
emains the major cause of morbidity and mortality
fter allogeneic stem cell transplantation (SCT). In
eneral, transplants from unrelated donors (UDs)
ave been more troublesome in this respect. Pretrans-
lantation serotherapy with anti-thymocyte globulin tATG) or other antibodies appears to reduce GVHD
nd mortality of closely matched UD bone marrow
ransplantation (BMT) to levels comparable to
atched related donor (MRD) BMT [1-10]. Although
he move from BM to blood as a stem cell source in
RD SCT has improved some outcomes, the inci-
ence of cGVHD in particular is higher [11,12]. It
herefore seemed rational to investigate the use of
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J. A. Russell et al300TG in MRD BCT. Since 1999 we have used rabbit
TG during the pretransplantation conditioning pro-
ocol for all such transplantations. We report a
atched pair analysis comparing outcomes of patients
eceiving MRD BCT with and without ATG.
ETHODS
atients
Eighty-two adults were treated with a ﬁrst my-
loablative BCT and pretransplantation ATG from
anuary 1999 until May 2002. An attempt was made to
atch each consecutive ATG recipient with a BCT
ecipient in the transplant database with the same
iagnosis and disease stage but not given ATG. The
atabase was searched backward from December 1998
able 1. Diagnoses of Each Group
Active Leukemia
Standard
Risk Intermediate Risk High Risk
ML 16 CR1 2 CR2 7 from MDS; 3 pif,
1 ref, 1 rel
LL 6 CR1 1 CR2 1 ref, 1 rel
ML 2 (AP/CP2)
LL 3 rel/ref
HL 8 rel/ref (2 mantle
cell,4 low grade, 1
intermediate grade,
1 high grade)
M 2
otal 22 18 14
DS indicates myelodysplasia; pif, primary induction failure; ref,
refractory; rel, relapsed; MM, multiple myeloma.
able 2. Patient and Treatment Characteristics
edian age (range)
onditioning
VP16 60 mg/kg  TBI 1200 cGy
VP16 60 mg/kg  TBI 500 cGy
Cyclophosphamide 120 mg/kg  TBI 1200 cGy
Cyclophosphamide 180 mg/kg  TBI 1200 cGy
Busulfan 4 mg/kg orally  4  cyclophosphamide 120 mg/kg
Busulfan 4 mg/kg orally  4  fludarabine 50 mg/m2  5
Busulfan 3.2 mg/kg i.v.  4  fludarabine 50 mg/m2  5
Busulfan 3.2 mg/kg i.v.  4  fludarabine 50 mg/m2  5  TBI
onor/recipient sex
Male/male
Male/female
Female/male
Female/female
onor/recipient CMV status
/
/
/
/P16 indicates etoposide.ntil the ﬁrst match was found, and this patient was
hen moved to the control group. The process was
epeated until there was no match for a given ATG
ecipient. Fifty-four ATG recipients were matched
ith 54 control patients from a total of 82 BCT
ecipients not given ATG. The diagnoses of the 2
roups are recorded in Table 1. There were no pa-
ients with chronic myelogenous leukemia (CML) in
rst chronic phase because BM was always used for
his diagnosis. Table 2 presents other details of pa-
ients and their treatments. Analysis took place in June
006 at which time surviving ATG recipients had
een followed for 49–89 mo (median, 72 mo) and
ontrol patients for 90–137 mo (median, 110 mo).
reatment
From 1996 donors were given a ﬁxed number of
ull vials of granulocyte-macrophage colony stimulat-
ng factor (GM-CSF) to provide a dose of 7.5-10
g/kg for 4 d. Progenitor cells were collected on day
usually in a single procedure. Before 1996 donors
ook part in a dose-ﬁnding study of GM-CSF [13].
Supportive care was similar for all patients. No
rotective isolation was used [14]. Single-donor plate-
ets were given to maintain counts 10  109/L and
BCs to keep hemoglobin levels 80 g/L. Growth
actors were not given routinely. Antibacterial and
ntipneumocystis prophylaxes comprised ciproﬂoxa-
in 500 mg 2 times daily and twice weekly tri-
ethoprim/sulfamethoxazole. Blood products were all
rom cytomegalovirus (CMV)-seronegative donors.
efore 2000 ganciclovir was given to patients who
ere CMV antibody positive and/or had an antibody-
ositive donor on clinical suspicion of CMV disease
ATG No ATG
42 (18-63) 41 (22-54)
1 26
2
2
2
15
7 7
36
y 10
19 19
11 15
10 12
14 8
9 12
9 11
10 11
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Low-Dose ATG for MRD BCT 301ith evidence of reactivation on serology and/or cul-
ure. After this time a policy of surveillance for pp65
ntigen and preemptive therapy with ganciclovir
as instituted. The aGVHD prophylaxis protocol
ncluded cyclosporin A (CSA) orally or i.v. twice
aily to maintain blood levels at 250–400 mol/L.
ethotrexate was given in doses of 15 mg/m2 i.v. on
ay 1 and 10 mg/m2 on days 3, 6, and 11. Folinic
cid 5 mg i.v. or orally was started 24 h after each
ose of methotrexate and continued every 6 h until
2 h before the next dose [15]. The study group
eceived rabbit ATG (Thymoglobulin, Genzyme,
ambridge, Mass) 4.5 mg/kg i.v. in divided doses
ver 3 d. To reduce reactions patients received 0.5
g/kg on the ﬁrst infusion followed by 2 doses of 2
g/kg. Each dose was given as a continuous infu-
ion over 4-8 h. The ﬁnal infusion was given on the
ay of transplantation. Premedication included
ethylprednisolone 40 mg i.v. every 12 h for 6
oses and Benadryl 50 mg i.v. before each dose of
TG.
If no aGVHD occurred CSA was tapered over 4-8
k with the intent to discontinue by 2-4 mo.
ngraftment
Daily blood cell counts were done until discharge,
ith BM aspirations at 3 mo for surviving patients and
s clinically indicated. Granulocyte engraftment was
eﬁned as a count 0.5  109/L. The platelet count
eeded to be20 109/L without transfusion for 3 d.
atients dying within 28 d were considered unevalu-
ble for engraftment. Failure of neutrophil and plate-
et levels to recover by day 42 in the absence of
ersistent malignancy or other apparent cause was
onsidered graft failure.
raft-versus-Host Disease
Acute GVHD was graded according to standard
riteria [16]. Diagnosis of cGVHD was consistent
ith a recently published consensus document [17].
iagnosis and grading was performed by physicians at
nset and during treatment, with later conﬁrmation
nd recording by data managers.
Death was considered to be related to GVHD if it
ccurred during treatment for GVHD and when the
rimary cause was infection or GVHD.
Acute GVHD was treated with prednisone or
ethylprednisolone initially while continuing CSA.
irst-line therapy for steroid-resistant aGVHD was
hymoglobulin 2 mg/kg every other day for 2-4
oses while CSA was withheld. Chronic GVHD was
reated with prednisone with or without CSA with
ntroduction of other agents if response was incom-
lete. ttatistical Analysis
Fisher exact test was applied to distribution of
umerical differences between groups and 2-tailed
test test for comparison of means.
Distributions of time to events were plotted on
aplan-Meier curves and compared using the log-
ank test, with patients being censored for relapse for
stimation of nonrelapse mortality. For time to onset
f cGVHD, patients were censored at time of death,
LI, or second transplantation. Analysis of time on
reatment for cGVHD censored patients at relapse (if
mmunosuppression was deliberately stopped at this
oint) or death. Analysis was performed on a Macin-
osh computer using GraphPad Prism (GraphPad
orp, San Diego, Calif). P values of .05-.1 are referred
o as trends and those .05 as signiﬁcant.
ESULTS
mmediate Toxicity
Despite premedication the ﬁrst infusion of ATG
as frequently accompanied by fever and chills. There
ere no severe immediate sequelae and serum sickness
as not seen. Reactions were generally absent or less
evere with the second and third doses.
ngraftment
One ATG recipient was not evaluable for engraft-
ent because of early death. All other patients under-
ent engraftment with neutrophils, and median time
o recovery was 16 d (range, 11–97 d) for ATG recip-
ents versus 15 d (range, 10–27 d) for controls. One
dditional ATG recipient failed to achieve platelet
ecovery before death from GVHD on day 50. Plate-
ets never decreased 20  109/L in 4 ATG recipi-
nts. Death on days 39–105 occurred before platelet
ecovery in 5 control patients and was attributed to
ersistent leukemia in 1 and transplant-related causes
n 4. In the remaining patients, platelets recovered in
median of 17 d (range, 8–106 d) for ATG recipients
ersus 16 d (range 11–109 d) for controls.
raft-versus-Host Disease
The actuarial incidence of aGVHD grades II-IV
as 19  5% in ATG recipients compared with 32 
% in controls (P  .1; Figure 1A). The ﬁgures for
rade III-IV disease were 6  3% and 13  5%,
espectively (P  NS; Figure 1B). Of 44 ATG recip-
ents with grade 0-I aGVHD, 38 lived150 d. Twenty-
ve discontinued CSA at 44–890 d (median, 81 d) and
3 developed cGVHD while still on CSA. Of 37
ontrol patients with grade 0-I aGVHD, 30 lived
150 d. Of these, 9 stopped CSA at 62–175 d (me-
ian, 104 d), and 21 developed cGVHD while still
aking CSA.
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J. A. Russell et al302Incidence of cGVHD at 2 yr was 55  8% with
TG versus 96 3% without ATG (P .002; Figure
c). Figure 2 shows the major sites of involvement by
GVHD. ATG recipients had fewer sites involved
han did the control group (mean, 2.1  0.2 versus
.8  0.2, P  .04). Those ATG patients with
GVHD were treated for a median of 393 d compared
ith 473 d for controls (P  NS; Figure 3).
elapse
Relapse rate at 4 yr was 43  7% for ATG recip-
ents and 22  7% in controls (P  .053; Figure 4A).
ight of 23 relapsing patients in the ATG group
Figure 1. Kaplan-Meier plots of (A) aGVHD gra
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tsFigure 2. Distributiourvived having achieved another remission (4) or dis-
ase stabilization (4) after more treatment. One of 12
ontrol patients who relapsed is currently alive in
emission after a second SCT.
ransplant-Related Mortality
Non-relapse mortality (NRM) was 4  3% versus
7  5% at 100 d and 9  4% versus 34  7% at 4 yr
P  .002) with and without ATG, respectively (Fig-
re 4B). Deaths were related to GVHD in 3 ATG-
reated patients versus 14 controls (P  .007). Table 3
resents the causes of early and later transplant-re-
V, (B) aGVHD grades III-IV, and (C) cGVHD.
LUNG GUT
ATG (n = 25)
NO ATG (n = 37)IVERn of cGVHD.
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Low-Dose ATG for MRD BCT 303ated deaths. In the control group 4-yr TRM was 30
% in 32 TBI recipients compared with 41  11% in
2 patients not given TBI (P  NS). Three of 7
atients given ﬂudarabine with oral busulfan without
TG died of treatment-related causes.
FS and Overall Survival
Projected disease-free survival (DFS) at 5 yr with
nd without ATG was 50  7% versus 49  7% (P 
S; Figure 5A) and survival was 66  7% versus 50
%, respectively (P  .046; Figure 5B).
igure 3. Kaplan-Meier plot of time to discontinuing treatment of
GVHD.
igure 4. Kaplan-Meier plots of (A) relapse and (B) nonrelapse
ortalities. FISCUSSION
One of the most signiﬁcant changes in the practice
f SCT in the past decade has been the increased use
f blood as the stem cell source [11,12]. This trend is
ustiﬁed by the results of randomized studies indicat-
ng a survival advantage for BCT in some patient
ubgroups [18-23]. However, the price for this may be
signiﬁcantly increased risk of cGVHD [11,12].
herefore, not only is GVHD still the main cause of
eath after BCT but also the quality of life of those
atients who do survive may be worse in general than
hat after BMT. We previously reported that unre-
ated BMT recipients given additional ATG have out-
able 3. Causes of Nonrelapse Death
Death before
Day 100*
Death after
Day 100*
Total
Deaths
TG
(n  54)
Myocardial infarct
(1), aGVHD
related (1)
cGVHD related (2) 4
o ATG
(n  54)
aGVHD related (7;
1 aspergillus),
interstitial
pneumonitis (1),
cardiac failure/
pulmonary
embolus (1)
cGVHD related (7;
2 aspergillus),
pneumonia (1),
cerebrovascular
accident (1)
21
Includes identiﬁed opportunistic infection when death was related
to GVHD.igure 5. Kaplan-Meier plots of (A) DFS and (B) overall survival.
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J. A. Russell et al304omes similar in every respect to MRD BMT patients
eceiving methotrexate/CSA alone [10]. Since 1999
ll MRD SCT recipients have received ATG in an
ttempt to reduce morbidity and mortality from
VHD. The current study indicates some success in
his respect, although the incidence of cGVHD is still
ubstantial in ATG-treated patients. We have seen
igher rates of cGVHD after BCT without ATG than
eported elsewhere [24]. Explanations could include
ifferences in managing immune suppression and/or a
ower threshold for clinical diagnosis. The lower in-
idence of cGVHD with ATG does not seem to result
rom differences in rates of CSA taper; most control
atients developed cGVHD while still on their initial
ourse of CSA. The control patients also had more
ites involved by cGVHD but duration of treatment
as similar. Although formal assessments were not
one, it is likely that overall quality of life was better
n ATG recipients. Even without an effect on survival,
here would therefore be an overall beneﬁt of ATG
iven in this way.
ATG seemed to inﬂuence death from aGVHD
nd cGVHD equally. Is it also likely that improved
reatment of GVHD may contribute to the lower
RM? We have little evidence to indicate that we
ave signiﬁcantly better treatments for GVHD than
ere previously available and our management of this
omplication did not change signiﬁcantly over the
tudy period.
The tendency to more relapse is compensated for
y reduced TRM leading to similar DFS ﬁgures.
ome of those patients who survive long enough to
elapse may be rescued by further treatment, a likely
xplanation for the improved overall survival. The
ffect on relapse is seen despite a thymoglobulin dose
omewhat lower than has been customary for UD
ransplantations so there may be no advantage in in-
reasing it. It would be preferable to prevent relapse if
t were possible without sacriﬁcing the beneﬁts of
TG in ameliorating the effects of GVHD. Conceiv-
bly the improved tolerability of the current regimen
ould allow some dose intensiﬁcation of the cytotoxic
gents. Thus addition of 400-cGy TBI to the ﬂudara-
ine and busulfan regimen may decrease relapse in
cute myelogenous leukemia (AML) without increas-
ng TRM [25].
The concern that ATG might result in excessive
mmune suppression causing post-transplantation
ymphoproliferative disease and opportunistic infec-
ion has not been justiﬁed. We saw no cases of post-
ransplantation lymphoproliferative disease and sig-
iﬁcant morbidity and mortality from opportunistic
nfection were seen only in the context of GVHD.
Some shortcomings of this study must be ad-
ressed. First, it was necessary to search our data base
ack to December 1994 to ﬁnd as many patients as
ossible for the matched control group. We have no evidence that outcomes of MRD transplantations
hanged signiﬁcantly between 1994 and 1998 [14].
ver the study period support protocols changed little
part from those for CMV, but there were no deaths
ttributed to CMV in either group.
Acute GVHD and cGVHD may be inﬂuenced by
reparative regimens and it is possible that this could
xplain some of our ﬁndings. More patients in the
ontrol group received full-dose, ie, 1200 cGy, TBI
nd most ATG-treated patients received i.v. busulfan,
hich gives more predictable drug exposures and is
etter tolerated than the oral form [26,27]. The pa-
ients in our control group given TBI developed no
ore TRM than did those receiving chemotherapy
lone. Thus the improved TRM in the ATG group is
nlikely to be from more control patients receiving
BI compared with oral busulfan. Could the use of i.v.
usulfan in the ATG group have contributed to the
mproved outcomes? Some of the beneﬁts of the i.v.
orm appear to be from a reduction in veno-occlusive
isease, which was not a serious issue in our control
atients. In our experience the regimen-related toxic-
ty has been similar with i.v. or oral busulfan, with the
xception of stomatitis, which seems somewhat less
ith the i.v. drug [28]. de Lima et al [29] reported that
n almost identical regimen to the one used in the
urrent study but without ATG was exceptionally well
olerated. It therefore remains possible that the i.v.
usulfan contributed to the reduced GVHD and
RM by exposing fewer busulfan-treated patients to
oxic drug levels. What inﬂuence may replacing cy-
lophosphamide with ﬂudarabine have had? Combi-
ations of oral busulfan with cyclophosphamide or
udarabine have had similar toxicities in our hands
28,30]. Three of 7 patients given ﬂudarabine with
ral busulfan without ATG died of treatment-related
auses in this study, circumstantial evidence that the
ubstitution of cyclophosphamide by ﬂudarabine did
ot contribute signiﬁcantly to the improved outcomes
n ATG recipients.
A recent analysis compared outcomes of patients
reated in Calgary with the daily i.v. busulfan/ﬂu-
arabine regimen and ATG with matched controls
iven busulfan/cyclophosphamide from the CIB-
TR database. A signiﬁcant (P  .003) survival
eneﬁt was documented for the ﬂudarabine/busul-
an group, largely attributable to lower TRM [31].
his study showed a very signiﬁcant (P  .0001)
eduction in aGVHD in the ATG-treated patients
ut no inﬂuence on cGVHD. Although there was
ess aGVHD in our ATG-treated group, this did
ot reach signiﬁcance, perhaps partly because of
mall patient numbers. The difference in the effect
n cGVHD is difﬁcult to explain. As noted above,
he incidence of cGVHD in our control patients
as high but consistent with our previous experi-
nce.
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Low-Dose ATG for MRD BCT 305A recent Italian study has documented a very sig-
iﬁcant effect of thymoglobulin on morbidity and
ortality from cGVHD in unrelated BMT recipients,
ﬁnding consistent with ours [32]. In addition, Deeg
t al [33] demonstrated a reduction in aGVHD and
GVHD in myelodysplasia patients given Thymo-
lobulin before MRD transplantation without a sig-
iﬁcant effect on DFS compared with concurrently
reated controls [33].
In conclusion we suggest that regimens based on
udarabine and oral or i.v. busulfan with pretransplan-
ation ATG added to methotrexate and CSA for re-
ipients of MRD BCT may result in less cGVHD,
ower TRM, and probably improved quality of life in
urvivors compared with previous protocols. The
hallenge of relapse remains.
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